Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Jul;7(Suppl 3):S75.
doi: 10.21037/atm.2019.03.58.

Immunotherapy for head and neck cancer: where are we now and where are we going?

Joshua M Bauml  1 , Charu Aggarwal  1 , Roger B Cohen  1
Affiliations
Editorial

Immunotherapy for head and neck cancer: where are we now and where are we going?

Joshua M Bauml et al. Ann Transl Med. 2019 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: JM Bauml discloses research funding to his institution from Merck, Incyte, Carevive Systems, Novartis, Bayer, Janssen, Astra Zeneca and Takeda. He discloses that he has performed consultative services for Bristol Myers Squibb, Astra Zeneca, Celgene, Merck, Janssen, Genentech, Guardant Health, Boehringer Ingelheim and Takeda; C Aggarwal discloses research funding to her institution from Genentech/Roche, Incyte, Macrogenics and Medimmune. She has performed consultative services for Genentech, Bristol Myers Squibb, and Lilly. An immediate family member is on a speakers’ bureau with Genentech, Novartis, and Pfizer; RB Cohen discloses research funding to his institution from Merck, Celldex, Innate, Macrogenics, HEAT, Genocea, and Xencor. He discloses that he has performed consultative services for Takeda, HEAT, Innate, and Genocea.

Comment on

References

    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7-30. 10.3322/caac.21387 - DOI - PubMed
    1. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27. 10.1056/NEJMoa0802656 - DOI - PubMed
    1. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016;17:956-65. 10.1016/S1470-2045(16)30066-3 - DOI - PubMed
    1. Chow LQM, Haddad R, Gupta S, et al. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol 2016;34:3838-45. 10.1200/JCO.2016.68.1478 - DOI - PMC - PubMed
    1. Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J Clin Oncol 2017;35:1542-49. 10.1200/JCO.2016.70.1524 - DOI - PMC - PubMed